Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2007

View Archived Issues

Merck & Co. reports preliminary in vivo results of novel DPP-IV inhibitor

Adenovirus-based HIV-1 vaccine safe in humans

Snapshots of new study results for epilepsy treatments

Enzon files IND for HIF-1alpha antagonist

Novel agents for treating neurological disorders disclosed in recent patents

New JAK3 inhibitors emerge from Rigel R&D

U.S. orphan drug status for INNO-406 in Gleevec-resistant or intolerant CML

Novel therapeutic agents for gastrointestinal disorders claimed in recent patents

Galapagos extends and expands drug discovery collaboration with Amgen

DOR receives payment from Sigma-Tau for rights to negotiate orBec alliance

Sequenom and Qiagen collaborate on prenatal diagnostics

OSI licenses GKA program for type 2 diabetes to Lilly

New phase IIb trial begins for microplasmin in vitrectomy

Xytis signs CRADA for neboglamine in cocaine addiction

Semafore completes Series B equity financing

Tengion studies urinary neobladder construct in phase II

ALK-Abello and Schering-Plough form immunotherapy alliance

Launch of Merck Serono

GSK completes acquisition of Domantis

TargeGen selects Jak2 inhibitor TG-101348 for clinical development

Shionogi and Nippon Kayaku end Japanese development agreement for NS-75B

ATC shows potential for combination therapy with tipranavir

HY-10275 meets endpoints in insomnia study

HGF gene plasmid shows potential to improve perfusion in patients with CLI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...